

EuroPCR@WCCI

April 15th, 2010
Warsaw, Poland



EuroPCR@WCCI

April 15th, 2010

Warsaw, Poland

8.45-9.00 Introduction and Welcome Address:

Professor Jean Marco, Chairman of EuroPCR;

Professor Adam Witkowski, Chairmen of WCCI;

Professor Robert J. Gil, Chairmen of WCCI.

Learning the techniques: patients with multivessel coronary artery disease

- Live case
- Live in-a-box case
- Discussion according to the PCR Learning the techniques tools
- Take-home message

Carotid artery stenting: from asymptomatic patients to acute carotid syndromes

Introduction & objectives

1/ State of the practice in Poland

Live demonstration 1.

2/ Debate

Carotid artery stenting in asymptomatic patients

- The Polish experience
- What the guidelines tell us?

Carotid artery stenting in symptomatic patients

- Polish practice/experience
- What the guidelines tell us?

Roundtable discussion: Are there any gaps? Are the guidelines adapted ? Are some actions to be identified?

Live demonstration 2.

3/ Are we ready to perform carotid artery stenting in acute carotid syndromes?

Roundtable discussion on acute carotid syndromes

Take-home message

Learning the techniques: Transcatheter Aortic Valve Implantation

- Live demo from the Institute of Cardiology in Warsaw: Edwards SAPIEN device
- Discussion according to the PCR Learning the techniques tools
- Live in-a-box from Toulouse: Medtronic CoreValve
- Discussion according to the PCR Learning the techniques tools
- Take-home message

Can we optimise the treatments modalities for STEMI patients?

Introduction & objectives

1/ Transportation , logistics and system network

- State of the practice in Poland
- State of the practice in other EU country : Spain
- Roundtable discussion : Are there any gaps? Are some actions to be identified?

2/ Be realistic: we still need thrombolysis in 2010

- Transportation constraints in Poland and lytic therapy
- Transportation timing and lytic therapy: what the ESC guidelines tell us?
- Roundtable discussion : Are there any gaps? Are some action to be identified?

3/ Concept of « optimal tailored adjunctive pharmacotherapy

4/ Primary PCI : device selection

- According to Polish constraints/regulation/experience
- What the ESC guidelines tell us?
- Roundtable discussion : Are there any gaps? Are some actions to be identified?

Take-home message